On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus by Ukrainski M et al.
International Journal of Diabetology & Vascular Disease Research, 2013 © 15
Ukrainski M,  Gandrabura T, Bischoff LN, Ahmed I (2013) On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus. Int J Diabetol Vasc Dis Res. 1(3), 15-18.
International Journal of Diabetology & Vascular Disease Research(IJDVR)
ISSN 2328-353X
                  On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus
            Review Article
Ukrainski M2,  Gandrabura T4 , Bischoff  LN3,  Ahmed I1*
1* Associate Professor of  Medicine, Thomas Jefferson University and Hospitals, 211-South, 9th Street, # 600, Philadelphia, PA 19107, USA. 
2 I  nternal Medicine Resident, Thomas Jefferson University Hospital, Philadelphia PA, USA.
3 Assistant Professor of  Medicine, Thomas Jefferson University and Hospitals, Philadelphia PA, USA.
4 Atlanticare Regional Medical Center, Atlantic City, NJ, USA.
*Corresponding Author: 
Intekhab Ahmed, M.D, FACP, FACE
Associate Professor of  Medicine, Thomas Jefferson University and Hos-
pitals, 211-South, 9th Street, # 600, Phila-delphia, 
PA 19107, USA.
Tel: 215-955-5752; Fax: 215-928-3160
E-mail: Intekhab.ahmed@jefferson.edu
Receiverd: Aprial 25, 2013
Accepted:  May 15, 2013
Published: May 20, 2013
Citation: Ukrainski M,  Gandrabura T, Bischoff  LN, Ahmed I (2013) 
On The Horizon: New Oral Therapies for Type 2 Diabetes Mel-
litus. Int J Diabetol Vasc Dis Res. 1(3), 15-18. doi: http://dx.doi.
org/10.19070/2328-353X-130004
Copyright: Ahmed I© 2014. This is an open-access article distributed 
under the terms of  the Creative Commons Attribution License, which 
permits unrestricted use, distribution and reproduction in any medium, 
provided the original author and source are credited.
Introduction 
Diabetes mellitus afflicts approximately 400 million people world-
wide and, without any significant change in this trend, by 2030 
more than 552 million people will be diabetic [1]. Our current 
treatment options are able to maintain reasonable glycemic con-
trol for a pe-riod of  time; however, they are unable to stop the 
pro-gression of  disease leading to deteriorating glycemic control 
over time and subsequent need for increasingly complicated treat-
ment regimens.
The two core defects of  type 2 diabetes mellitus (T2DM) are in-
sulin resistance and pancreatic beta cell dysfunction or failure [2]. 
Insulin resistance appears to be the first and main defect resulting 
in an increased demand of  insulin release from beta cells to nor-
malize glucose levels. Overtime, the beta cells’ ability to main-tain 
this level of  hyperinsulinemia deteriorates result-ing in the hyper-
glycemia characteristic of  T2DM. In-sulin resistance is attributed 
to ectopic lipid deposition in liver, skeletal muscle, and changes 
in adipose tissue resulting in inflamed tissue leading to the release 
of  a multitude of  inflammatory cytokines and decreased release 
of  favorable cytokines and hormones [3,4]. By the time a person 
develops diabetes, 50-80% of  insulin secretory function of  beta 
cells is lost [4]. Additional factors influencing beta cell dysfunc-
tion include aging, genetic factors and biochemical abnormalities 
like li-potoxicity, glucotoxicity, inflammation, amyloid depo-sition, 
and reactive oxygen species [5].
Current therapies for T2DM are based on targeting these two 
core defects. Metformin and sufonylureas (SUs) are by far the 
most commonly prescribed medi-cations for T2DM manage-
ment. Unfortunately, they are unable to arrest the natural course 
of  decline in beta cell function, their effects are not long lasting
[6], and they each carry their own side effect profile, with hypo-
glycemia of  particular concern with SU use. Thiazolidinediones 
(TZD’s) improve insulin sensitivity but are notorious for their side 
effects such as fluid retention, weight gain, fracture, and poten-
tial risk of  bladder cancer [7,8]. Members of  the incretin fam-
ily include DPP-IV inhibitors and glucagon like peptide (GLP-1) 
analogs and each have their own limitations. The former have a 
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limited effect on A1c reduction and a potentially increased risk of  
pancreatitis, while the latter are injectable and also carry the risk 
of  pancrea-titis [9,10].
New therapies, while continuing to address the same two core de-
fects, are being designed to also target various molecular pathways 
involved in the pathogenesis of  T2DM, normalize hyperglycemia, 
and minimize the complications of  T2DM.
Sodium-coupled glucose co-transporter 2 inhibi-tors 
(SGLT2 inhibitors)
The kidneys play a significant role in maintaining glu-cose ho-
meostasis via the filtration and reabsorption of  glucose. The re-
absorption of  glucose predominantly occurs on the brush border 
membrane of  the convo-luted segment of  the proximal tubule. 
Glucose enters the tubular cells by a sodium-dependent active 
carrier-mediated transport process and exits via the basolat-eral 
membrane by facilitated diffusion utilizing a so-dium-independ-
ent glucose transporter (GLUTs) [11]. The sodium-dependent 
glucose co-transporters are a family of  glucose transporters 
found in the intestinal mucosa of  the small intestine (SGLT1) and 
the proxi-mal tubule of  the nephron (SGLT2, predominantly, and 
SGLT1) [12]. SGLT1 and SGLT2 are members of  the SLC5A 
gene family (also known as the sodium substrate symporter gene 
family. Twelve of  these have been identified in the human ge-
nome, and several of  these (including SGLT1 and SGLT2) are 
associated with sodium glucose transport. These transporters use 
the electrochemical sodium gradient generated by the Na+/K+-
ATPase is the driving force for the sym-porter activity. SGLT2 is 
the principal transporter and is responsible for 90% of  glucose 
reabsorption in the kidney. SGLT2 is expressed in the S1 segment 
of  the proximal tubule while SGLT1 is expressed in the S3 seg-
ment of  proximal tubule and estimated to account for 10% of  
glucose reabsorption [11.12].
Sodium-coupled glucose co-transporter 2 inhibitors are a class of  
agents initially derived from phlorizin, a natural component of  
apple tree bark, that blocks glu-cose reabsorption in the proximal 
tubule of  the kidney [13].
T2DM patients have increased activity of  SGLT2 re-sulting in 
increased glucose reabsorption [14] and, therefore, its inhibition 
is a logical site for intervention. Several oral SGLT2 inhibitors are 
in different phases of  clinical trial. Canagliflozin, Dapaglifozin, 
Ipragli-fozin, Topoglifozin, and Empaglifozin are the most stud-
ied drugs in this class. The FDA recently approved Canagliflozin, 
with the requirement that five post-mar-keting studies be done 
including: a study to examine cardiovascular outcomes, a pharma-
covigilance pro-gram to report the incidences of  malignancies, se-
vere pancreatitis, liver abnormalities, adverse events during preg-
nancy; a study to evaluate bone safety, and two pediatric studies 
[15]. Dapaglifozin is approved for use in European Union but its 
approval is delayed in USA due to concerns about an imbalance 
in breast and bladder cancer events with more cases developing 
in patients taking the drug [16]. The drop in hemoglobin A1c 
(HbA1c) with most of  these drugs is in the range of  0.7-0.96% 
with modest weight loss, which is dose dependent, and ranges 
from 1.35 kg with small dose and 2 kg with maximum tolerable 
doses [17]. Some side effects of  these agents include hypoglyce-
mia, urinary tract infections, genital mycotic infections, salt and 
volume depletion, and other electrolyte losses such as calcium and 
magnesium [16,17]. It has not been ap-proved for patients with 
significant renal impairment and those requiring hemodialysis. 
If  further data on safety and efficacy continues to be reassuring, 
SGLT2 inhibitors have a promising future in the management of  
diabetes.
Ranolazine
Ranolazine, an anti-anginal medication with proven cardiovascu-
lar safety profile, acts by inhibiting late sodium current in car-
diac tissue [18]. Its mechanism of  action for glucose lowering 
is unknown, but may include augmentation of  glucose induced 
insulin re-lease and a beta cell protective effect [20]. A post-hoc 
analysis of  a study using Ranolazine in T2DM patients revealed 
that the participants on Ranolazine had a lower HbA1c. The pla-
cebo adjusted drop in HbA1c after four months of  treatment 
was 0.42-0.59% . An-other notable finding is that the patients on 
ranolazine did not have a significant difference in hypoglycemic 
episodes when compared to placebo, and also did not change the 
incidence of  hypoglycemic episodes in pa-tients already on anti-
hyperglycemic therapies, includ-ing sulfonylureas [19,20].
Salicylate derivatives
The use of  salicylates for the treatment of  diabetes was proposed 
over 100 years ago based on the obser-vation that diabetic pa-
tients taking salicylates showed improvement in their blood sugar 
[21]. Our under-standing of  T2DM as a result of  a chronic in-
flamma-tory state has reinvigorated the interest in salicylates as 
a therapeutic option for T2DM. The proposed mecha-nism of  
action is via inhibition of  NF-kB, which in-creases the produc-
tion of  proinflammatory cytokines, promoting insulin resistance 
and down-regulating the insulin-sensitizing adiponectin [21,22]. 
Some studies have reported evidence that salicylates also directly 
inhibit adipocyte lipolysis resulting in decreased FFA levels and 
increased insulin sensitivity. Multiple small clinical trials have been 
done to evaluate the effect of  salicylates on T2DM. Most of  these 
are limited by small sample size and length of  study. They also 
required very high doses of  salicylates to achieve the effect, and 
these were associated with numerous side effects, particularly gas-
trointestinal bleeding, tinnitus, and hearing loss [23]. Salsalate, a 
nonacetylated salicy-late, is a promising new therapy for T2DM. 
Salsalate does not affect the COX enzymes, making it a much 
safer and tolerable option at higher doses than aspirin and other 
acetylated salicylates. One study examining the benefit of  salsalate 
in T2DM revealed a significant dose-dependent drop in HbA1c, 
of  up to 0.49% with 4g of  salsalate. Potential concerns include 
mild in-creases in microalbumin to creatinine ratio and in LDL 
cholesterol [23-25].
Peroxisome proliferator activator receptor ago-nists 
(PPAR’s)
The PPAR’s are a group of  nuclear receptors known as ligand-
inducible transcription factors, which play di-verse roles in regu-
lating growth and metabolism. There are three major isotypes, 
PPAR-α, -γ and -δ. They form heterodimers with retinoid X re-
ceptors (RXR) to ei-ther stimulate or repress gene transcription. 
PPAR-α is mainly expressed in liver, heart, and kidney and plays 
a role in fatty acid oxidation and lipoprotein metabolism.PPAR-γ 
is expressed in adipose tissue, macrophages, and osteoblasts. It 
is involved in adipose tissue dif-ferentiation and triglyceride syn-
thesis. PPAR-δ is ex-pressed in skeletal muscle, cardiac muscle, 
and adipose tissue, where it stimulates fat oxidation[26]. It also is 
expressed in liver and immune cells where it has a role in reduc-
ing hepatic glucose production and inflamma-tion, respectively.
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TZDs are an example of  PPAR-γ agonists, and have had a major 
impact on reducing insulin resistance to date. Unfortunately, their 
use has dramatically de-creased due to their potential untoward 
side effects.The first TZD, Troglitazone, was associated with liver 
toxicity; Rosiglitazone showed increased cardiovascu-lar morbid-
ity, and pioglitazone is linked with a poten-tially increased risk of  
bladder cancer and osteoporosis [8]. These side effects appear to 
be secondary to the non-selectivity of  these molecules. Because 
of  their impressive effectiveness in T2DM, there is an ongoing 
effort to develop second generation of  PPAR agonists with more 
selective action and fewer side effects.
Balaglitazone, a newer partial PPAR-y agonist, has been sug-
gested to be as efficacious in lowering blood glucose with less 
adverse systemic effects [24,25]. In the BALLET trial, Henriksen 
et al, compare the effects of  balaglitazone to pioglitazone. Af-
ter 26 weeks, 10mg of  balaglitazone lowered HbA1c by 0.99%, 
compared to -1.11% for 20mg balaglitazone, and -1.22% for pi-
oglitazone 45-mg . This study also showed that bala-glitazone was 
effective in reducing total insulin require-ments and increased in-
sulin sensitivity. While there were no statistically significant differ-
ences in adverse effects between the two agents, the 10mg dose 
of  bala-glitazone showed a trend towards less weight gain, flu-id 
retention, cardiovascular complications, and effects on bone den-
sity. Multiple phase III trials are underway in Europe and US to 
further examine balaglitazone.
Aleglitazar is a member of  a new class of  dual PPAR-γ and -β 
agonists, named glitazars, which is being inves-tigated in phase III 
trials. Aleglitazar has been reported to improve HbA1c, triglycer-
ides, and HDL in a dose dependent manner [26].
Given these promising results, these agents have great potential 
for management of  T2DM.
Therapies targeting metabolic enzymes
11β Hydoroxysteroid dehydrogenase type 1 
(11β -HSD1) inhibitors
The role of  glucocorticoids in adipose tissue metabo-lism and 
distribution, lipid and glucose metabolism has long been known, 
with high levels of  glucocorticoids promoting hyperglycemia and 
insulin resistance, hy-perlipidemia, and visceral obesity [27, 28]. 
11β- HSD is an enzyme that is involved in the interconversion of  
cortisol and cortisone and is present in two isoforms,11β- HSD1 
and 11β- HSD2 . 11β-HSD1 is predomi-nantly expressed in the 
liver and adipose tissue and its main function appears to be con-
version of  cortisone to cortisol [27]. 11β-HSD2 is primarily ex-
pressed in the kidneys and colon and acts to inactivate cortisol by 
converting it to cortisone [27-31].
The incentive to develop 11β-HSD1 inhibitors for the treat-
ment of  diabetes has come from our increased understanding 
of  the role between glucocorticoid ex-cess and insulin resist-
ance. The potential benefits of  developing compounds that in-
hibit 11β-HSD1 include weight loss, decreased serum insulin and 
glucose lev-els, decreased LDL and TG [27, 30, 31]. However, 
many compounds that have an inhibitory effect on 11β-HSD1, 
also inhibit 11β-HSD2. For example, carbenoxolone is a non-
selective inhibitor of   both 11β-HSD1 and 11β-HSD2 derived 
from licorice root.
In type 2 diabetics, it was found to improve hepatic insulin sen-
sitivity, but also led to sodium retention, hypertension, and hy-
pokalemia due to its 11β-HSD2 inhibition [29,31]. 11β-HSD1 
inhibitory effects have been demonstrated in previously known 
compounds including rosiglitazone, estrogens, which may help 
to explain the protective effect they demonstrate in pre-meno-
pausal women, and fibrates [31]. Many new 11β-HSD1 selective 
compounds are in development, which include INCB13739, an 
antisense oligonucleo-tide. In one study, INCB13739 was added 
to metform-in, resulting in an average reduction in HbA1c of  
0.6% and up to 1.1kg weight loss. Concerning limitations include 
interference with the hypothalamic-pituitary-adrenal (HPA) axis 
leading to mineralocorticoid excess resulting in sodium retention, 
hypertension, viriliza-tion, and menstrual irregularities [30,31]. 
While the potential utility of  these compounds is clear, phase III 
studies are needed to determine the safety and efficacy of  these 
11β-HSD1 inhibitors.
Glucokinase activators
Glucokinase (GK) or hexokinase IV, is an enzyme that catalyzes 
the addition of  phosphate to glucose for fur-ther intracellular me-
tabolism. It serves as a glucose sensor in beta cells and initiates 
the release of  insulin from the beta cell. In the liver, this enzyme 
directs glu-cose toward glycogen synthesis and lipogenesis. In dia-
betics, activity of  GK is preserved, although decreased due to 
a lesser number of  functional beta cells [32]. Currently, several 
GK activators are undergoing stud-ies to evaluate their efficacy 
and safety. This class of  molecules targets beta cell core defect in 
T2DM and liver production of  glucose. In a phase I trial, piragi-
latin resulted in a decrease in fasting and post-prandi-al glucose 
in mild diabetics [32]. Concerns include a time-dependent effect 
on the central nervous system and reproductive system due to the 
expression of  GK in these tissues.
Protein Tyrosine Phosphatase 1B (PTP1B) inhibitors
This enzyme acts as a negative regulator of  insulin signaling by 
deactivating the insulin receptor. Current data shows its inhibition 
improves both insulin and leptin action in animals [33]. It may be 
an option for the treatment of  diabetes, but due to its expression 
in multiple other tissues, other studies are needed to en-sure selec-
tivity of  these inhibitors to the desired tis-sues.
Fructose-1,6-bisphosphatase (FBP) inhibitors
FBP is a rate-limiting enzyme for gluconeogenesis and its inhibi-
tion can result in improved blood sugars. A small phase I trial 
showed improvement in fasting blood sugars in individuals with 
diabetes [34].
Conclusion
In the coming years, multiple new therapeutic options will be 
available to address hyperglycemia and its unde-sirable side ef-
fects. These new therapeutics show great promise for controlling 
and managing T2DM, but are by no means a cure. The corner 
stone of  prevention of  T2DM lies in healthy lifestyle. Dietary 
modification and adequate physical activity is the ideal interven-
tion for keeping the threat of  diabetes development and its com-
plications at bay. We should continue to emphasize and allocate 
resources to the education and prevention of  T2DM rather than 
solely depending on treating dia-betes after it has occurred
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